While both in vitro and in vivo studies showed the potential of iNOS inhibitors as effective treatments for gliomas, no clinical trials on gliomas have been published (Figure 4) (Mazurek and Rola, 2021; Tripathi et al., 2023). Here, NOS2 is linked to central nervous system cancer.